Five PK metrics + S×F interaction [Regulatives / Guidelines]

posted by AngusMcLean – USA, 2014-11-11 20:22 (4244 d 17:33 ago) – Posting: # 13859
Views: 16,730

I think it may be applied to other MP bimodal formulations. I would study the fundamental release aspects of Concerta in vitro and invivo. Then I would think of analogous metrics as is appropriate for your drug of interest. In other words make a plan in case you are asked to include partial exposure metrics.

If it applies to Concerta I myself can see no reason why this would not be applied to other bimodal drugs.

Any comments,

Angus

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
215 visitors (0 registered, 215 guests [including 15 identified bots]).
Forum time: 14:55 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5